Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis

Antoniou, 2003, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies, Am J Hum Genet, 72, 1117, 10.1086/375033 Pal, 2005, BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases, Cancer, 104, 2807, 10.1002/cncr.21536 Boyd, 2001, BRCA: the breast, ovarian, and other cancer genes, Gynecol Oncol, 80, 337, 10.1006/gyno.2001.6131 Ford, 1994, Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium, Lancet, 343, 692, 10.1016/S0140-6736(94)91578-4 Narod, 1995, Genetic heterogeneity of breast-ovarian cancer revisited. Breast cancer linkage consortium, Am J Hum Genet, 57, 957 Easton, 1995, Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium, Am J Hum Genet, 56, 265 Easton, 1997, Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12–13, Am J Hum Genet, 61, 120, 10.1086/513891 Moslehi, 2000, BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer, Am J Hum Genet, 66, 1259, 10.1086/302853 Struewing, 1997, The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N Engl J Med, 336, 1401, 10.1056/NEJM199705153362001 Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer Incidence in Five Continents. Lyon; 2005. Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 Atchley, 2008, Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer, J Clin Oncol, 26, 4282, 10.1200/JCO.2008.16.6231 Dolle, 2009, Risk factors for triple-negative breast cancer in women under the age of 45 years, Cancer Epidemiol Biomarkers Prev, 18, 1157, 10.1158/1055-9965.EPI-08-1005 Key, 2001, Epidemiology of breast cancer, Lancet Oncol, 2, 133, 10.1016/S1470-2045(00)00254-0 Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al., editors. SEER cancer statistics review, 1975–2006. Bethesda, MD: National Cancer Institute; 2009. Quinn, 2009, BRCA1 and implications for response to chemotherapy in ovarian cancer, Gynecol Oncol, 113, 134, 10.1016/j.ygyno.2008.12.015 Riman, 1998, Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence, Clin Endocrinol (Oxf), 49, 695, 10.1046/j.1365-2265.1998.00577.x McGuire, 2004, Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations, Am J Epidemiol, 160, 613, 10.1093/aje/kwh284 Whittemore, 1992, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case–control studies. II. Invasive epithelial ovarian cancers in white women, Am J Epidemiol, 136, 1184, 10.1093/oxfordjournals.aje.a116427 King, 2003, Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, 302, 643, 10.1126/science.1088759 Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713–27. Beral, 2008, Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls, Lancet, 371, 303, 10.1016/S0140-6736(08)60167-1 Haynes, 1994, Developing optimal search strategies for detecting clinically sound studies in MEDLINE, J Am Med Inform Assoc, 1, 447, 10.1136/jamia.1994.95153434 Shojania, 2001, Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy, Eff Clin Pract, 4, 157 Narod, 2002, Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst, 94, 1773, 10.1093/jnci/94.23.1773 Heimdal, 2002, Oral contraceptives and risk of familial breast cancer, Cancer Detect Prev, 26, 23, 10.1016/S0361-090X(02)00004-1 Haile, 2006, BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50, Cancer Epidemiol Biomarkers Prev, 15, 1863, 10.1158/1055-9965.EPI-06-0258 Gronwald, 2006, Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland, Breast Cancer Res Treat, 95, 105, 10.1007/s10549-005-9051-5 Brohet, 2007, Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS collaborating group, J Clin Oncol, 25, 3831, 10.1200/JCO.2007.11.1179 Runnebaum, 2001, Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives, Pharmacogenetics, 11, 635, 10.1097/00008571-200110000-00010 Whittemore, 2004, Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations, Br J Cancer, 91, 1911, 10.1038/sj.bjc.6602239 McLaughlin, 2007, Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case–control study, Lancet Oncol, 8, 26, 10.1016/S1470-2045(06)70983-4 Antoniou, 2009, Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the international BRCA1/2 carrier cohort study, Cancer Epidemiol Biomarkers Prev, 18, 601, 10.1158/1055-9965.EPI-08-0546 Ursin, 1997, Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?, Cancer Res, 57, 3678 Jernstrom, 2005, Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing, Eur J Cancer, 41, 2312, 10.1016/j.ejca.2005.03.035 Sade, 2006, Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers, Eur J Cancer, 42, 650, 10.1016/j.ejca.2005.08.045 Lee, 2008, Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study, Cancer Epidemiol Biomarkers Prev, 17, 3170, 10.1158/1055-9965.EPI-08-0396 Modan, 2001, Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation, N Engl J Med, 345, 235, 10.1056/NEJM200107263450401 Modugno, 2003, Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States), Cancer Causes Control, 14, 439, 10.1023/A:1024932427503 DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 Sterne, 2002, Statistical methods for assessing the influence of study characteristics on treatment effects in ‘meta-epidemiological’ research, Stat Med, 21, 1513, 10.1002/sim.1184 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Thompson, 1999, Explaining heterogeneity in meta-analysis: a comparison of methods, Stat Med, 18, 2693, 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V Greenland, 1992, Methods for trend estimation from summarized dose–response data, with applications to meta-analysis, Am J Epidemiol, 135, 1301, 10.1093/oxfordjournals.aje.a116237 van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med JID – 8215016 2002;21:589–624. Copas, 2001, A sensitivity analysis for publication bias in systematic reviews, Stat Methods Med Res, 10, 251, 10.1191/096228001678227776 Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med JID – 8215016 2001;20:641–54. SAS Institute Inc. SAS windows version. (8.02). Cary, NC: 1999.